← boothcheck

INCY vs ULS stock comparison

INCYTE CORPORATION vs UL Solutions Inc., two Biotechnology stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.

Incyte actually makes drugs, chiefly Jakafi, and it shows in the margin: 26.71 cents of profit per sales dollar, against UL Solutions' 11.27% from safety testing and certification. Incyte carries no debt, earns 25.46% on equity, and trades at 16.07 times earnings and 4.18 times book. UL Solutions earns a similar 26.2% on equity but costs far more, 57.6 times earnings and 15.13 times book, because the market treats certification cash as more dependable than pharma cash. Incyte is the larger company at $23.5B to $20.2B, and its free-cash yield of 6.45% comfortably beats the 2.23% on offer at UL Solutions.

Comparison updated 2026-07-11.

INCY vs ULS: the numbers

MetricINCYULS
Price$116.75$87.26
Market cap$24.1B$17.8B
SectorBiotechnologyBiotechnology
StageGrowthMature
Implied growth (priced in)+11.7%
P/E16.550.7
P/B4.2913.32
P/S4.505.73
EV/EBITDA12.729.9
Revenue growth+21.3%+6.9%
Operating margin23.7%18.2%
Net margin26.7%11.3%
Return on equity25.5%26.2%
Return on assets19.5%11.8%
Return on invested capital25.3%24.5%
FCF yield6.3%2.5%
Dividend yield0.6%
Debt / equity0.000.27
Current ratio3.681.16
Altman Z (solvency)7.627.52
Piotroski F (quality)6 / 96 / 9
Full INCY report → Full ULS report →
Get boothcheck's read on INCY and ULS, and what their prices are betting on, in your inbox. No hype, no spam.
Free. Informational only, not investment advice. Unsubscribe anytime.

Compare any two stocks

vs

The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.